References
[1] Prashant Pradhan, Ashutosh Kumar Pandey, Akhilesh Mishra, Parul Gupta1, Praveen Kumar Tripathi1, Manoj Balakrishnan Menon1, James Gomes1, Perumal Vivekanandan and Bishwajit Kundu, Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag, bioRxiv, doi: https://doi.org/10.1101/2020.01.30.927871.
[2] Jasper Fuk-Woo Chan, Kin-Hang Kok, Zheng Zhu, Hin Chu, Kelvin Kai-Wang To, Shuofeng Yuan & Kwok-Yung Yuen, Genomic characterization of the 2019 novel human pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan, Emerging Microbes & Infections, 2020.
[3] Berend Jan Bosch, Ruurd van der Zee, Cornelis A. M. de Haan, and Peter J. M. Rottier, The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex, JOURNAL OF VIROLOGY, Aug. 2003, p. 8801–8811 Vol. 77, No. 16.
[4] R.Savino, LCiapponi, A.Lahm1, A.Demartis, A.Cabibbo, C.Toniatti, PRDelmastro2, S.Altamura and G.Ciliberto3, Rational design of a receptor super-antagonist of human interleukin-6, The EMBO Journal vol.13 no.24 pp.5863-5870, 1994.
[5] Ravinder Reddy Gaddam, Stephen Chambers and Madhav Bhatia, ACE and ACE2 in Inflammation: A Tale of Two Enzymes, Inflammation & Allergy - Drug Targets, 2014.
[6] Hai-Yan Jin, Bei Song, Gavin Y. Oudit, Sandra T. Davidge, Hui-Min Yu, Yan-Yan Jiang,
Ping-Jin Gao1,2, Ding-Liang Zhu1,2, Guang Ning1, Zamaneh Kassiri3, Josef M. Penninger6, Jiu- Chang Zhong, ACE2 Deficiency Enhances Angiotensin II-Mediated Aortic Profilin-1 Expression, Inflammation and Peroxynitrite Production, PLoS ONE, June 2012, Volume 7, Issue 6.
[7] Ruiz-Ortega M, Esteban V, Rupérez M, Sánchez-López E, Rodríguez-Vita J, Carvajal G, Egido J, Renal and vascular hypertension-induced inflammation: role of angiotensin II. , Curr Opin Nephrol Hypertens. 2006 Mar;15(2):159-66.
[8] Tianxi Cai, ScD; Yichi Zhang, PhD; Yuk-Lam Ho, MPH; Nicholas Link, BA; Jiehuan Sun, PhD; Jie Huang, MS; Tianrun A. Cai, MD; Scott Damrauer, MD;, Association of Interleukin 6 Receptor Variant With Cardiovascular Disease Effects of Interleukin 6 Receptor Blocking Therapy A Phenome-Wide Association Study, JAMACardiology.
[9] Mohammed A.R. Chamsi-Pasha, MD1, Zhili Shao, MD PhD2, and W. H. Wilson Tang, MD2, Angiotensin-Converting Enzyme 2 as a Therapeutic Target for Heart Failure, Curr Heart Fail Rep, 2015.
[10] David Gurwitz, Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics,2020, https://doi.org/10.1002/ddr.21656.
[11] Julio Caballero, Considerations for Docking of Selective Angiotensin-Converting Enzyme Inhibitors, molecules, 2020, 25, 295.
[12] Lanying Du, Yuxian He, Yusen Zhou, Shuwen Liu, Bo-Jian Zheng∥, and Shibo Jiang, The spike protein of SARS-CoV — a target for vaccine and therapeutic development, Nat Rev Microbiol. 2009 March ; 7(3): 226–236.
[13] Haibo Zhang, Josef M. Penninger, Yimin Li, Nanshan Zhong and Arthur S. Slutsky, Angiotensin‑converting enzyme 2 (ACE2) as a SARS‑CoV‑2 receptor: molecular mechanisms and potential therapeutic target, Intensive Care Med, 2020.
[14]Yun Chen et al., Biochemical and Biophysical Research Communications, 2020.
[15] Vaidya KA, Kadam AV and Nema V, Anti-Retroviral Drugs for HIV: Old and New, Austin Journal of HIV/AIDS Research, 2016.
[16] Álvaro H. Borges,1 Jemma L. O’Connor,2 Andrew N. Phillips,2 Frederikke F. Rönsholt,3 Sarah Pett,2,4,5 Michael J. Vjecha,6 Martyn A. French,7,8 and Jens D. Lundgren1; for the INSIGHT SMART and ESPRIT Study Groups and the SILCAAT Scientific Committee, Factors Associated With Plasma IL-6 Levels During HIV Infection, JID 2015:212.
[17] Faustina Nkechi Osuji1, Charles Chinedu Onyenekwe, Joseph Ebere Ahaneku and Nkiruka Rose Ukibe, The effects of highly active antiretroviral therapy on the serum levels of proinflammatory and anti-inflammatory cytokines in HIV infected subjects, Osuji et al. Journal of Biomedical Science (2018) 25:88.
[18] Christine Rogez-Kreuz1, Benjamin Mane´ glier1, Marc Martin1, Nathalie Dereuddre-Bosquet, Jacques Martal, Dominique Dormont and Pascal Clayette, Involvement of IL-6 in the anti-human immunodeficiency virus activity of IFN-s in human macrophages, International Immunology, Vol. 17, No. 8, pp. 1047–1057.
[19] By Rachel A. Burke, Pharm.D., BCACP; and Nicole D. White, Pharm.D., Biologic Disease-Modifying Antirheumatic Drugs, PSAP 2014.
[20] H. Haibel and C. Specker, Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis, CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2009.
[21]Yousuke Furuta et al., T-705 ( favipiravir) and related compounds, Antiviral Research, 82(2009) 95-102.
[22] Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Ahmed Kotb, Robin ChristensenAmy S Mudano, Lara J Maxwell, Nipam P Shah, Peter Tugwell, George A Wells, Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease‐modifying anti‐rheumatic drugs: a systematic review and network meta‐analysis, https://doi.org/10.1002/14651858.CD012183.
[23] WHO Model Formulary 2008.
,